{"id":224567,"date":"2025-11-05T08:13:31","date_gmt":"2025-11-05T14:13:31","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/11\/from-blood-to-solid-tumors-a-new-way-to-power-up-car-t-cell-therapy"},"modified":"2025-11-05T08:13:31","modified_gmt":"2025-11-05T14:13:31","slug":"from-blood-to-solid-tumors-a-new-way-to-power-up-car-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/11\/from-blood-to-solid-tumors-a-new-way-to-power-up-car-t-cell-therapy","title":{"rendered":"From blood to solid tumors: A new way to power up CAR T cell therapy"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/from-blood-to-solid-tumors-a-new-way-to-power-up-car-t-cell-therapy.jpg\"><\/a><\/p>\n<p>Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized cancer treatment\u2014but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a major challenge because they are difficult for CAR T cells to infiltrate and are often highly heterogeneous, making them harder to target with a single therapy.<\/p>\n<p>Researchers at Monash University, in collaboration with scientists from the Peter MacCallum Cancer Center, used CRISPR-based gene editing or a PTPN2 inhibitor to enhance the function of human CAR T cells engineered to recognize an antigen expressed on many <a href=\"https:\/\/medicalxpress.com\/tags\/solid+tumors\/\" rel=\"tag\" class=\"\">solid tumors<\/a>.<\/p>\n<p>The study, led by Professor Tony Tiganis and Dr. Florian Wiede, was <a href=\"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.adk0627\" target=\"_blank\">published<\/a> in Science Translational Medicine.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized cancer treatment\u2014but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a major challenge because they are difficult for CAR T cells to infiltrate and are often highly heterogeneous, making them harder [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11],"tags":[],"class_list":["post-224567","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/224567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=224567"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/224567\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=224567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=224567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=224567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}